3 ASX 300 stocks up by more than 300% in a year

These stocks certainly add up to a triple treat.

| More on:
Three women cruise along enjoying ice-creams in the sunshine.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As we approach the final month of trading for another year, it's exciting to look back and see which ASX 300 stocks are on track to deliver the best share price growth this year.

The S&P/ASX 300 Index (ASX: XKO) is currently tracking at 19.5% growth over the past 12 months.

That's obviously a great result.

But hang on to your hats as we reveal the 3 ASX 300 stocks that are up by more than 300% over the past 12 months.

Triple treat: 3 ASX 300 stocks shooting the lights out

Based on data provided by S & P Global Market Intelligence, there are only 3 stocks in the ASX 300 that have recorded 300% growth or more over 12 months.

1. Zip Co Ltd (ASX: ZIP)

This ASX 300 financial stock is having an absolute screamer!

The Zip share price has soared by 817.8% over the past 12 months. No kidding.

Zip shares knocked out a two-and-a-half-year high of $3.53 this month.

The buy now, pay later company is on the comeback trail after a messy few years that saw it abandon its plans for global expansion and refocus on core markets and earlier profitability.

Wilson Asset Management portfolio manager, Tobias Yao says the ASX 300 financial stock's recovery has been driven by growth in its US business.

In the latest lot of quarterly results, Zip reported a 43% increase in US business earnings, beating market expectations.

Looking ahead, Yao commented:

We think Zip Co will be a beneficiary of any interest rate cuts in Australia with consumer sentiment, spending and credit quality likely to improve.

We continue to see strong momentum in the business and see the potential for further earnings upgrades over the course of the year.

Zip shares closed at $3.35 on Tuesday.

2. Clarity Pharmaceuticals Ltd (ASX: CU6)

This ASX 300 radiopharmaceutical stock has risen by 348.2% over the past 12 months. In September, Clarity Pharmaceuticals' share price reached an all-time high of $8.98.

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company seeking to develop novel products to fight various types of cancer.

This year, the market has been very optimistic about Clarity's trials of its prostate cancer treatment, 67Cu-SAR-bisPSMA.

As we covered in April, a patient had a "complete response" to cycles of treatment with 67Cu-SAR-bisPSMA. This meant there was no detectable cancer on test results at the end of the treatment.

The ASX 300 healthcare stock closed at $5.75 on Tuesday.

3. Mesoblast Ltd (ASX: MSB)

Fellow ASX 300 biotech stock, Mesoblast is up by 336.4% over the past 12 months. The Mesoblast share price reached a three-year high of $1.83 this month.

After years of work and setbacks in gaining approval from the United States Food and Drug Administration (FDA), Mesoblast resubmitted its lead drug Ryoncil for consideration in July.

Ryoncil, or remestemcel-L, treats steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The FDA has previously rejected the drug and demanded more studies.

The company expects a decision by 7 January 2025.

Mesoblast certainly seems confident and has already arranged funding for an immediate launch.

In September, the company announced a convertible note subscription with its largest shareholder to give it access to funds if the FDA finally gives Ryoncil the green light.

Under the agreement, Mesoblast can issue up to US$50 million in convertible notes in US$10 million tranches over 90 days if the FDA approves Ryoncil.

The ASX 200 biotech share closed at $1.71 on Tuesday.

Motley Fool contributor Bronwyn Allen has positions in Mesoblast and Zip Co. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Zip Co. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Best Shares

A happy couple drinking red wine in a vineyard.
Best Shares

5 ASX 200 shares just upgraded to strong buy ratings

The experts say these 5 shares are set to rise over the next 12 months.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Best Shares

If I could only own 1 ASX stock, it would be this one

This stock offers investors a bit of everything.

Read more »

a girl stands in an apple orchard holding two red apples in raised arms with a happy, celebratory look on her face with a large smile and a pretty country background to the picture.
Best Shares

Top ASX shares to buy in March 2025

Looking to plant some new investment seeds right now?

Read more »

A woman walks along the street holding an oversized box wrapped as a gift.
Best Shares

Top ASX shares to buy following earnings surprises

Who doesn't love a surprise?

Read more »

Businessman smiles with arms outstretched after receiving good news.
Best Shares

Here are 3 of my most profitable investments in ASX shares ever (and which one I'd buy more of right now)

I reckon only one of these shares is worthy of a buy today.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Best Shares

Top oversold ASX shares to buy in February 2025

Hoping to bag an investment bargain this month?

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Best Shares

6 ASX 200 shares that could benefit from a weak Australia Dollar

This expert reckons a low dollar is unearthing opportunities.

Read more »

Two kids are selling big ideas from a lemonade stand on the side of the road for cheap!
Best Shares

Top ASX shares to buy in February 2025

Worried there are no great-value ASX shares left to buy? Our Foolish writers reckon these five are worth a good…

Read more »